The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s (NYSE: PFE) Inlyta, reports The ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an ...

Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Detailed price information for Clearside Biomedi (CLSD-Q) from The Globe and Mail including charting and trades.

Fintel reports that on March 18, 2025, RBC Capital initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform ...

Clearside Biomedical (NASDAQ:CLSD – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a ...

The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

(RTTNews) - Innovent Biologics Inc. and HUTCHMED (China) Limited announced that the FRUSICA-2 Phase 2/3 clinical trial, which evaluated sintilimab in combination with fruquintinib as second-line ...

Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib ...

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side ...